Rooted in 20+ years of research
A University of Reading spin-out, building on two decades of foundational venom science that underpins our oral therapy.
Timing Foundation phase complete
Pipeline
From lab to field:
From lab to field:
the path to global reach
Our development journey, from foundational research to a tiered global rollout.
-
01 Discovery Completed 
-
02 Preclinical Completed Tested against the world's most medically significant snakes
Our oral therapy targets the venom families responsible for the majority of global envenomings, including vipers, elapids and other medically significant species.
Timing Preclinical validation across 15+ venoms
-
03 Clinical Current phase Moving into first-in-human trials
Our clinical trial plan (CT04) is published, with Phase I safety studies in preparation, followed by Phase II in snakebite patients.
Timing Phase I ~early 2026, Phase II ~July 2026
-
04 Approval Upcoming A regulatory path designed for field realities
Routes include CDSCO emergency authorisation, WHO prequalification for onward reach through LMICs, and animal-rule consideration for high-income markets.
Timing First approvals targeted ~October 2026
-
05 Deployment Upcoming Built to reach where antivenom cannot
A heat-stable oral format means treatment can be stocked in clinics, pharmacies and field kits, not just hospitals with cold chain.
Timing First launch targeted late 2026
-
06 Global reach Phased A path to 125+ countries
A tiered rollout from first market, through fast-follow LMICs, bridging markets and high-income approvals.
Timing Phased rollout, late 2026 onwards
What’s next
Partners and investors
For deeper technical, regulatory or commercial detail, we share briefings directly with partners and investors under confidentiality.